|
👥1) Indications & clinical contexts CHA2DS2‑VASc is used to stratify ischemic stroke risk in non‑valvular AF adults across outpatient follow‑up, inpatient evaluation and disease management. Not recommended for routine use without AF. 🧮2) Scoring items Age ≥75 years +2Age 65–74 years +1Female sex +1Hypertension / Heart failure / Diabetes / Vascular disease each +1Prior stroke / TIA +2🧭3) How to use this calculator 1On the homepage, click “Start now” or the top button to jump to the calculator. 2Choose age, sex and medical history as prompted, then click “Calculate risk score”. 3Review the total and risk category; check “Recommendations” and “Notes”. 📊4) Interpretation & clinical notes 0 · Low risk Anticoagulation generally not indicated 1 · Low–moderate risk Assess with individual factors and bleeding risk 2–3 · Moderate risk Most patients should discuss anticoagulation 4–5 · High–moderate risk Anticoagulation usually recommended ≥6 · High risk Strongly recommend anticoagulation and close follow‑up Scores do not equal treatment plans; consider bleeding risk, comorbidities and patient preferences under clinician judgment. 📚5) Evidence & guideline notes CHA2DS2‑VASc is widely reflected in global guidelines for AF risk stratification, with strong low‑risk identification. Sex‑removed CHA2DS2‑VA has been discussed; follow current guidance and local practice. FAQ What is the CHADS2VASc (CHA2DS2‑VASc) score? A clinical score estimating ischemic stroke risk in atrial fibrillation (AF). Versus CHADS₂, it enhances discrimination and low‑risk identification. Who should use the chads2vasc calculator? Mainly non‑valvular AF adults for stroke risk stratification; not advised for routine use in non‑AF populations. What do the risk categories mean? 0: low; 1: low–moderate; 2–3: moderate; 4–5: high–moderate; ≥6: high. Consider anticoagulation as appropriate. Why does female sex add 1 point? Female sex correlates with risk and adds +1 in classic CHA2DS2‑VASc; some guidance discusses the sex‑removed CHA2DS2‑VA—follow current local policy and judgment. Does the score replace clinician judgment? No. It supports stratification. Management considers comorbidities, bleeding risk and preferences, decided by qualified clinicians. (责任编辑：) |